The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase 1 dose-escalation study of BBI503, a first-in-class cancer stemness kinase inhibitor in adult patients with advanced solid tumors.
Scott Andrew Laurie
No relevant relationships to disclose
Derek J. Jonker
No relevant relationships to disclose
William Jeffery Edenfield
No relevant relationships to disclose
Joe Stephenson
No relevant relationships to disclose
Deborah Keller
No relevant relationships to disclose
Matthew Hitron
Employment or Leadership Position - Boston Biomedical
Wei Li
Employment or Leadership Position - Boston Biomedical
Youzhi Li
Employment or Leadership Position - Boston Biomedical
Keyur Gada
Employment or Leadership Position - Boston Biomedical
Yuan Gao
Employment or Leadership Position - Boston Biomedical
Chiang Li
Employment or Leadership Position - Boston Biomedical